GlassScriptPhysician profile
Jawad Zafar
NPI 1922427376
$14,870.24
in general payments reported to CMS, 2019-2025
41 companies · $6,727 in 2025
The $6,727 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2020: $1,034 · 2021: $1,437 · 2022: $1,494 · 2023: $1,753 · 2024: $1,535 · 2025: $6,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,886 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,300 · Travel and Lodging: $1,471 · Education: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,886.02 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,300.00 |
| Travel and Lodging | $1,471.13 |
| Education | $356.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $4,594.91 | 2025 | Cobenfy |
| Abbvie INC. | $1,095.56 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $1,064.16 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $999.79 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $743.57 | 2020-2025 | Caplyta |
| Pfizer INC. | $688.15 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $629.85 | 2019-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $575.83 | 2019-2024 | Trintellix |
| Lundbeck LLC | $497.11 | 2019-2025 | Rexulti |
| Braeburn INC. | $403.42 | 2023-2025 | Brixadi |
| Corium, LLC | $343.89 | 2022-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $320.74 | 2019-2025 | Spravato, Invega Sustenna, Xarelto |
| Sunovion Pharmaceuticals INC. | $318.45 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $299.54 | 2022-2024 | Jornay Pm |
| Neurocrine Biosciences, INC. | $273.40 | 2020-2025 | Ingrezza |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jawad Zafar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.